Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first‐line sunitinib: a medical chart review across ten centers in five European countries-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first‐line sunitinib: a medical chart review across ten centers in five European countries

Published:2014-07-18 Issue:6 Volume:3 Page:1517-1526
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Porta Camillo¹,Levy Antonin²,Hawkins Robert³,Castellano Daniel⁴,Bellmunt Joaquim⁵,Nathan Paul⁶,McDermott Ray⁷,Wagstaff John⁸,Donnellan Paul⁹,McCaffrey John¹⁰,Vekeman Francis¹¹,Neary Maureen P.¹²,Diaz Jose¹²,Mehmud Faisal¹²,Duh Mei Sheng¹³

Affiliation:

1. IRCCS San Matteo University Hospital Foundation Pavia Italy

2. Institut Gustave Roussy Paris France

3. School of Cancer and Imaging Sciences University of Manchester Manchester United Kingdom

4. Hospital 12 de Octubre Madrid Spain

5. Hospital del Mar‐IMIM Barcelona Spain

6. Mount Vernon Cancer Centre Northwood Middlesex United Kingdom

7. Adelaide & Meath Hospital Tallaght Dublin Ireland

8. South West Wales Cancer Institute Singleton Hospital Swansea United Kingdom

9. University College Hospital Galway Galway Ireland

10. Mater Misericordiae Hospital Dublin Ireland

11. Groupe d'analyse Ltée Montréal Québec Canada

12. GlaxoSmithKline Collegeville Pennsylvania

13. Analysis Group Inc. Boston Massachusetts

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.302

Reference18 articles.

1. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis

2. Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma

3. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

4. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

5. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early follow-up of outpatients with oral anticancer therapy in the ONCORAL multidisciplinary community-hospital program;The Oncologist;2024-09-14

2. Profile of adverse drug reactions reported via the Continuum+ platform: Results from three-year regional follow-up;Therapies;2024-04

3. Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study;Clinical Genitourinary Cancer;2023-10

4. Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma;Targeted Oncology;2023-02-24

5. Patients’ self-management of adverse events and patient-reported outcomes in advanced renal cell carcinoma treated with targeted therapies: A prospective, longitudinal, observational study;Journal of Patient-Reported Outcomes;2022-12-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3